🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT07814274
Starting soon Observational

Prospective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development

NCT07814274 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2026-09-15
Last updated
2026-09-10

Condition(s) studied

Inflammatory Bowel Disease (IBD)

Investigational drug(s) / intervention(s)

De-identified Intestinal Ultrasound Data Collection

De-identified Intestinal Ultrasound Data Collection: Intestinal ultrasound images and cine loops will be collected from adults undergoing ultrasound as part of routine clinical care. Following informed consent, the images and cine loops will be de-identified and used for artificial intelligence algorithm development, training, tuning, and testing. The study does not assign participants to receive an intervention, and the ultrasound is not performed solely for research purposes. The artificial intelligence algorithms developed using the data will not be used to guide participant care or provide individual diagnostic results during the study.

Study summary

This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier to assess bowel inflammation.

The study will include adults who are healthy or who are having an intestinal ultrasound as part of care for inflammatory bowel disease, such as Crohn disease or ulcerative colitis. Researchers want to find out whether a computer program can measure bowel wall thickness from ultrasound images as accurately as experienced ultrasound clinicians. They will also explore whether the program can identify other changes in the bowel.

Participants will have an intestinal ultrasound as part of their usual care. People who agree to take part will allow the research team to use de-identified ultrasound images and a small amount of related health information. No medication, experimental treatment, or additional ultrasound procedure will be given for this study. The computer program will not be used to make decisions about a participant's care, and participants will not receive individual results from the program.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 18 years or older. * Individuals who are either healthy with no known finding of inflammatory bowel disease before the ultrasound examination or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. * Individuals who are able and willing to provide informed consent for the collection and use of de-identified study data. Exclusion Criteria: * Individuals who do not meet the study demographic requirements. * Individuals unable or unwilling to provide informed consent. * Pregnant individuals. * Individuals with health conditions managed using drugs or medical-device intervention, or with unmanaged conditions or conditions requiring monitoring, that could affect study eligibility or the ultrasound assessment. * Individuals who have recently taken contrast-enhancing compounds.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IBD Centre of BC Vancouver British Columbia

More University of British Columbia trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07814274 on ClinicalTrials.gov ↗ ← All trials in Canada